Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics Limited has announced the issuance of unquoted equity securities, specifically options and performance rights, as part of their employee incentive scheme. This move involves the issuance of nearly 3 million options expiring in 2032 and over 790,000 performance rights, which are not intended to be quoted on the ASX. This issuance is likely aimed at motivating and retaining key employees, potentially impacting the company’s operational dynamics and aligning employee interests with long-term company goals.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Average Trading Volume: 326,026
Technical Sentiment Signal: Buy
Current Market Cap: A$81.23M
See more insights into NUZ stock on TipRanks’ Stock Analysis page.